Treatment of amd using aav sflt-1
AssigneeAvalanche Australia Pty Ltd.
InventorsIan J. Constable, P. Elizabeth Rakoczy, Chooi-May Lai, Thomas W. Chalberg, JR.
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions and methods for the prevention or treatment of ocular neovascularization, such as AMD, in a human subject, by administering subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector comprising a nucleic acid encoding soluble Fms-related tyrosine kinase-1 (sFlt-1) protein to the human subject.
Claims24
1-41. (canceled)
A pharmaceutical composition comprising a nucleic acid sequence encoding an anti-VEGF protein operatively linked to a promoter sequence.
A unit dose of a pharmaceutical composition, the unit dose comprising at most 1×1013 vector genomes of recombinant virus comprising a nucleic acid that encodes for an anti-VEGF protein.
Dependencies are inferred from the claim text.